Study of a drug combo for relapsed or refractory lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. It aims to see if this new mix can help when standard therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called CD20-positive diffuse large B-cell lymphoma, confirmed by a biopsy.
- You must be at least 18 years old and able to perform daily activities with some help (ECOG score 0-3).
- Your lymphoma did not get better after first-line treatment, or came back within a year, or failed after two or more treatments, or returned more than 6 months after a stem cell transplant using your own cells.
- You must have at least one tumor that can be measured on a scan (at least 1.5 cm for lymph nodes or 1.0 cm for other organs, and visible on PET/CT).
- You must be willing and able to give informed consent and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new sequence of chemotherapy drugs for people with intermediate-to-high risk diffuse large B-cell lymphoma who did not achieve complete remission after their first two cycles of standard treatment. The goal is to see if this approach is safe and effective.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
This study tests a combination of four drugs (sonrotoclax, glofitamab, gemcitabine, and oxaliplatin) for people with large B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests an experimental drug called HMPL-760 combined with a standard chemo-immunotherapy regimen (R-GemOx) for people whose diffuse large B-cell lymphoma (DLBCL) has come back or stopped responding to treatment. The goal is to see if adding HMPL-760 works better than the standard approach alone.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.